SG10202006685XA - Treatment of Cancers Using Anti-NKG2A Agents - Google Patents
Treatment of Cancers Using Anti-NKG2A AgentsInfo
- Publication number
- SG10202006685XA SG10202006685XA SG10202006685XA SG10202006685XA SG10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancers
- treatment
- nkg2a
- agents
- nkg2a agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462067642P | 2014-10-23 | 2014-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202006685XA true SG10202006685XA (en) | 2020-08-28 |
Family
ID=54347541
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202006685XA SG10202006685XA (en) | 2014-10-23 | 2015-10-23 | Treatment of Cancers Using Anti-NKG2A Agents |
SG11201701388UA SG11201701388UA (en) | 2014-10-23 | 2015-10-23 | Treatment of cancers using anti-nkg2a agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701388UA SG11201701388UA (en) | 2014-10-23 | 2015-10-23 | Treatment of cancers using anti-nkg2a agents |
Country Status (11)
Country | Link |
---|---|
US (2) | US10329348B2 (en) |
EP (2) | EP3659625A1 (en) |
JP (1) | JP6889660B2 (en) |
KR (1) | KR102598068B1 (en) |
CN (1) | CN107073116A (en) |
AU (1) | AU2015334886B9 (en) |
CA (1) | CA2959841A1 (en) |
IL (1) | IL250677B (en) |
RU (1) | RU2721271C2 (en) |
SG (2) | SG10202006685XA (en) |
WO (1) | WO2016062851A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012009755A (en) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Stable antibody containing compositions. |
AU2012268939B2 (en) | 2011-06-17 | 2017-05-04 | Novo Nordisk A/S | Selective elimination of erosive cells |
JP2017538660A (en) | 2014-09-16 | 2017-12-28 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Treatment plan using anti-NKG2A antibody |
KR20230088521A (en) | 2014-09-16 | 2023-06-19 | 이나뜨 파르마 에스.에이. | Neutralization of inhibitory pathways in lymphocytes |
SG10202006685XA (en) | 2014-10-23 | 2020-08-28 | Innate Pharma | Treatment of Cancers Using Anti-NKG2A Agents |
US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
HUE054356T2 (en) | 2016-01-21 | 2021-09-28 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
DE102017001875A1 (en) * | 2017-02-27 | 2018-08-30 | Wolfgang Würfel | Drug for malignant treatment |
DE102017005815A1 (en) * | 2017-06-20 | 2018-12-20 | Wolfgang Würfel | Vaccine for the treatment of a malignancy |
EP3652207A1 (en) * | 2017-07-10 | 2020-05-20 | Innate Pharma | Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer |
WO2019165307A1 (en) * | 2018-02-23 | 2019-08-29 | Abexxa Biologics, Inc. | Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen |
US11464840B2 (en) | 2018-02-26 | 2022-10-11 | Swey-Shen Chen | Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers |
CN112004828A (en) | 2018-03-13 | 2020-11-27 | 依奈特制药公司 | Treatment of head and neck cancer |
JP2021531255A (en) * | 2018-07-23 | 2021-11-18 | アベクサ バイオロジクス,インク. | Antibodies targeting complexes containing non-classical HLA-I and neoantigens, and how to use them |
US20220259306A1 (en) * | 2018-11-07 | 2022-08-18 | Shanghai Hyamab Biotech Co., Ltd. | Nkg2a antibody, preparation method therefor and application thereof |
PE20211284A1 (en) | 2018-11-16 | 2021-07-19 | Bristol Myers Squibb Co | ANTI-NKG2A ANTIBODIES AND USES OF THEM |
JP2022553927A (en) * | 2019-10-14 | 2022-12-27 | イナート・ファルマ・ソシエテ・アノニム | Treatment of cancer with ILT-2 inhibitors |
US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
US10981997B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
AR126001A1 (en) * | 2021-06-01 | 2023-08-30 | Symphogen As | ANTI-NKG2A ANTIBODIES AND COMPOSITIONS |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122637A (en) | 1872-01-09 | Improvement in vapor-burners | ||
CU22545A1 (en) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5459061A (en) | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
DK0586002T3 (en) | 1992-08-18 | 2000-06-19 | Centro Inmunologia Molecular | Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
IT1277827B1 (en) | 1995-03-01 | 1997-11-12 | Ministero Uni Ricerca Scient E | CHIMERIC MURINE/HUMAN MONOCLONAL ANTIBODY OR ITS FRAGMENT SPECIFIC FOR THE EGF RECEPTOR (EGF-R) |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6794494B1 (en) | 2003-04-14 | 2004-09-21 | Arius Research, Inc. | Cancerous disease modifying antibodies |
CN1239701C (en) | 2000-05-19 | 2006-02-01 | 梨树化学株式会社 | Humanised antibodies to epidermal growth factor receptor |
RU2297245C2 (en) | 2001-02-19 | 2007-04-20 | Мерк Патент Гмбх | Modified anti-egfr antibodies with reduced ammonogenicity |
US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
ES2552281T3 (en) | 2001-05-11 | 2015-11-26 | Ludwig Institute For Cancer Research Ltd. | Specific binding proteins and uses thereof |
CN100497389C (en) | 2001-06-13 | 2009-06-10 | 根马布股份公司 | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1421113A4 (en) | 2001-08-03 | 2005-04-13 | Commw Scient Ind Res Org | Methods of screening based on the egf receptor crystal structure |
ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
JP2004126818A (en) | 2002-09-30 | 2004-04-22 | Toshiba Corp | Electronic equipment system, battery unit, and operation control method for battery unit |
AU2003304145A1 (en) | 2002-10-18 | 2004-12-13 | Macrogenics, Inc. | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP3803790B2 (en) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | Novel diabody-type bispecific antibody |
BRPI0411852A (en) | 2003-06-27 | 2006-05-23 | Abgenix Inc | antibodies directed to epidermal growth factor receptor deletion mutants and their uses |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
EP1701979A2 (en) | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
MXPA06011796A (en) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | FCgammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF. |
AU2005244058B2 (en) | 2004-05-10 | 2011-07-28 | Macrogenics, Inc. | Humanized FcgammaRIIB specific antibodies and methods of use thereof |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
ES2557325T5 (en) | 2004-12-28 | 2023-11-15 | Innate Pharma Sa | Monoclonal antibodies against NKG2A |
NZ556286A (en) | 2005-02-07 | 2010-11-26 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
WO2006133148A2 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
SI2573114T1 (en) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
JP2009529331A (en) | 2006-03-10 | 2009-08-20 | マクロジェニクス,インコーポレーテッド | Identification and engineering modification of antibodies having mutated heavy chains and methods of use thereof |
WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
EP2035452B1 (en) | 2006-06-22 | 2012-04-25 | Novo Nordisk A/S | Soluble heterodimeric receptors and uses thereof |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
RU2499001C2 (en) | 2006-06-30 | 2013-11-20 | Ново Нордиск А/С | Antibodies to nkg2a and their applications |
AR062223A1 (en) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE |
EP2247619A1 (en) * | 2008-01-24 | 2010-11-10 | Novo Nordisk A/S | Humanized anti-human nkg2a monoclonal antibody |
SG174963A1 (en) | 2009-03-31 | 2011-11-28 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
MX2012009755A (en) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Stable antibody containing compositions. |
ME03447B (en) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
AU2012268939B2 (en) * | 2011-06-17 | 2017-05-04 | Novo Nordisk A/S | Selective elimination of erosive cells |
CA2959318A1 (en) | 2014-08-28 | 2016-03-03 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations |
KR20230088521A (en) | 2014-09-16 | 2023-06-19 | 이나뜨 파르마 에스.에이. | Neutralization of inhibitory pathways in lymphocytes |
JP2017538660A (en) | 2014-09-16 | 2017-12-28 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Treatment plan using anti-NKG2A antibody |
SG10202006685XA (en) | 2014-10-23 | 2020-08-28 | Innate Pharma | Treatment of Cancers Using Anti-NKG2A Agents |
HUE054356T2 (en) | 2016-01-21 | 2021-09-28 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
-
2015
- 2015-10-23 SG SG10202006685XA patent/SG10202006685XA/en unknown
- 2015-10-23 JP JP2017521559A patent/JP6889660B2/en active Active
- 2015-10-23 KR KR1020177011228A patent/KR102598068B1/en active IP Right Grant
- 2015-10-23 WO PCT/EP2015/074581 patent/WO2016062851A1/en active Application Filing
- 2015-10-23 EP EP20150368.7A patent/EP3659625A1/en active Pending
- 2015-10-23 RU RU2017107559A patent/RU2721271C2/en active
- 2015-10-23 CN CN201580057597.6A patent/CN107073116A/en active Pending
- 2015-10-23 SG SG11201701388UA patent/SG11201701388UA/en unknown
- 2015-10-23 AU AU2015334886A patent/AU2015334886B9/en active Active
- 2015-10-23 US US15/521,401 patent/US10329348B2/en active Active
- 2015-10-23 CA CA2959841A patent/CA2959841A1/en active Pending
- 2015-10-23 EP EP15784685.8A patent/EP3209687A1/en not_active Withdrawn
-
2017
- 2017-02-20 IL IL250677A patent/IL250677B/en active IP Right Grant
-
2019
- 2019-06-21 US US16/448,016 patent/US11225519B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR102598068B1 (en) | 2023-11-06 |
US20190322744A1 (en) | 2019-10-24 |
SG11201701388UA (en) | 2017-03-30 |
JP6889660B2 (en) | 2021-06-18 |
CA2959841A1 (en) | 2016-04-28 |
US10329348B2 (en) | 2019-06-25 |
RU2017107559A (en) | 2018-11-27 |
IL250677B (en) | 2021-03-25 |
AU2015334886B9 (en) | 2021-07-08 |
EP3659625A1 (en) | 2020-06-03 |
AU2015334886A1 (en) | 2017-03-16 |
AU2015334886B2 (en) | 2021-06-10 |
RU2017107559A3 (en) | 2019-04-15 |
US11225519B2 (en) | 2022-01-18 |
IL250677A0 (en) | 2017-03-30 |
US20170313773A1 (en) | 2017-11-02 |
KR20170070076A (en) | 2017-06-21 |
RU2721271C2 (en) | 2020-05-18 |
EP3209687A1 (en) | 2017-08-30 |
CN107073116A (en) | 2017-08-18 |
JP2017537069A (en) | 2017-12-14 |
WO2016062851A1 (en) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250677B (en) | Treatment of cancers using anti-nkg2a agents | |
IL259783A (en) | Methods of treatment of malignancies | |
GB201701673D0 (en) | Methods of well treatment | |
FI3851537T3 (en) | Treatment of hyperbilirubinemia | |
HUE053654T2 (en) | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer | |
IL247267A0 (en) | Improved methods for the treatment of vascularizing cancers | |
HK1231561A1 (en) | Cancer treatment | |
IL263835A (en) | Exosome-guided treatment of cancer | |
GB201416832D0 (en) | Methods of treatment | |
GB201408297D0 (en) | Treatment of cancer | |
GB201412010D0 (en) | Treatment of hypertransaminasemia | |
GB201411027D0 (en) | Treatment | |
GB201417456D0 (en) | Treatment of cancer | |
GB201512139D0 (en) | Methods of treatment | |
GB201407837D0 (en) | Methods of cancer therapy | |
GB201622214D0 (en) | treatment of cancer | |
GB201417465D0 (en) | Treatment of cancers | |
GB201604621D0 (en) | Treatment of cancer | |
GB201604293D0 (en) | Treatment of cancer | |
GB201409362D0 (en) | Treatment of cancer | |
PT3851537T (en) | Treatment of hyperbilirubinemia | |
GB201405449D0 (en) | Treatment of cancer | |
GB201405075D0 (en) | Treatment of cancer | |
GB201512723D0 (en) | Treatment of cancer | |
GB201507928D0 (en) | Treatment of cancer |